Metagen Therapeutics (President and CEO: Taku Nakahara, PhD; Headquarters: Yamagata, Japan; hereinafter referred to as “MGTx”) has announced a JPY 1.1B investment in its Series A funding as of April, 2023. MGTx has been accelerating […]
Aurealis Therapeutics, a synthetic biology company developing ground-breaking cell and gene therapies for high unmet medical needs, has raised over $10 million through a Series A financing round co-led by Lynx Financial and TESI (Finnish […]
Pragma Bio, the technology-enabled platform for drug discovery formerly known as VastBiome, announced it has raised an additional $10 million in equity to continue its development of proprietary methods in genomic sequencing, artificial intelligence and […]
Basel, Switzerland, and Hørsholm, Denmark, March 13th 2023 – Bacthera, a specialized contract development and manufacturing organization (CDMO), announced today that it has acquired a cGMP manufacturing site in León (ES) from 4D Pharma. Acquiring […]
Biose Industrie, a contract development manufacturing organisation (CDMO) and a world-leader of live biotherapeutic product (LBP) process development and production, announced today their plan to open a laboratory in the heart of Boston, Massachusetts, later […]
L-GAM and the French State through the “French Tech Souveraineté” scheme have signed a purchase agreement with the aim of acquiring joint control of Biose Industrie, a world leader in the development and production of […]
Prokarium, a biopharmaceutical company leading the oncology field of microbial immunotherapy, has raised $30 million in new funding. This follows Prokarium’s announcement of partnering with Ginkgo Bioworks to leverage its world-class Foundry and extensive Codebase […]
ADM (NYSE: ADM), one of the world’s leaders in science-backed nutrition solutions, announced that it has opened a new production facility in Valencia, Spain to help meet rising global demand for probiotics, postbiotics and other […]
Finch Therapeutics Group, Inc. (the “Company,” “Finch,” or “Finch Therapeutics”) (Nasdaq: FNCH) today announced its decision to discontinue the PRISM4 Phase 3 trial of CP101 in recurrent C. difficile infection (CDI) and focus on realizing the value […]
Leveraging a year of important research updates, funding rounds, and academic papers, this report compiles the most significant industry news pertaining to microbiome drug development in 2022. It finds that the regulatory approval of three […]
Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), today announced the signing of a definitive agreement for a $20 million financing round, to […]